A computer model can prioritize peptides expected to bind an immune display molecule or appear among its ligands. The prediction helps select candidates for testing.
NetMHCpan-4.0 combined peptide-binding affinity data with eluted-ligand data, which also contain information about processing and natural presentation. Those training signals and prediction tasks should be distinguished. A consortium comparison assessed candidate tumor epitopes using measured immune interactions and developed improved prioritization features. A model score is a prediction with a validation setting; it is not an observation of peptide display, tumor recognition or patient benefit. The NetMHCpan-4.1 documentation expresses binder thresholds as percentile rank, the position of a predicted score against the scores of random natural peptides, and lets the user set the strong and weak binder thresholds, so a 0.4 per cent rank places a candidate within the top 0.4 per cent of that reference and is not a 99.6 per cent probability of presentation, recognition or benefit. The server predicts binding of a peptide to an MHC molecule of known sequence, and its model is trained on more than 850,000 binding-affinity and mass-spectrometry eluted-ligand peptides, two different training signals (Reynisson and colleagues, 2020). A model trained on more than 185,000 peptides eluted from 95 single-allele cell lines improved prediction of presented peptides (Sarkizova and colleagues, 2020). In a consortium study, 608 predicted epitopes were then tested for T-cell binding in patient-matched samples, a separate experiment from the prediction (Wells and colleagues, 2020), so expression, processing, display, T-cell receptor recognition and sparing of healthy tissue remain to be shown after a favourable score.
Shares Immunopeptidomics, Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen.
Shares Immunopeptidomics, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Immunopeptidomics, Peptide binding, presentation and immune recognition, Neoantigen.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/